Drug Profile

ABP 300 - Cancer

Alternative Names: ABP-300 - Cancer

Latest Information Update: 28 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abpro Therapeutics
Developer Abpro Therapeutics; Essex Bio-Technology
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

28 Aug 2022 No recent reports of development identified for research development in Chronic-lymphocytic-leukaemia in USA
28 Aug 2022 No recent reports of development identified for research development in Non-Hodgkin's-lymphoma in USA
30 Jul 2018 Early research in Chronic lymphocytic leukaemia in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com